ACXP vs. GANX, CNTB, FBLG, STTK, PDSB, ELYM, OSTX, CELU, VNRX, and IMMX
Should you be buying Acurx Pharmaceuticals stock or one of its competitors? The main competitors of Acurx Pharmaceuticals include Gain Therapeutics (GANX), Connect Biopharma (CNTB), FibroBiologics (FBLG), Shattuck Labs (STTK), PDS Biotechnology (PDSB), Eliem Therapeutics (ELYM), OS Therapies (OSTX), Celularity (CELU), VolitionRx (VNRX), and Immix Biopharma (IMMX). These companies are all part of the "pharmaceutical products" industry.
Acurx Pharmaceuticals vs.
Gain Therapeutics (NASDAQ:GANX) and Acurx Pharmaceuticals (NASDAQ:ACXP) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, profitability, community ranking, institutional ownership, analyst recommendations, risk, media sentiment, earnings and dividends.
Gain Therapeutics' return on equity of -203.91% beat Acurx Pharmaceuticals' return on equity.
Acurx Pharmaceuticals has lower revenue, but higher earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Acurx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Gain Therapeutics has a beta of 0.14, suggesting that its share price is 86% less volatile than the S&P 500. Comparatively, Acurx Pharmaceuticals has a beta of -1.72, suggesting that its share price is 272% less volatile than the S&P 500.
12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 11.5% of Acurx Pharmaceuticals shares are held by institutional investors. 11.7% of Gain Therapeutics shares are held by company insiders. Comparatively, 29.6% of Acurx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Gain Therapeutics received 20 more outperform votes than Acurx Pharmaceuticals when rated by MarketBeat users. However, 93.75% of users gave Acurx Pharmaceuticals an outperform vote while only 71.43% of users gave Gain Therapeutics an outperform vote.
Gain Therapeutics currently has a consensus target price of $7.25, indicating a potential upside of 228.05%. Acurx Pharmaceuticals has a consensus target price of $12.00, indicating a potential upside of 1,438.46%. Given Acurx Pharmaceuticals' higher possible upside, analysts plainly believe Acurx Pharmaceuticals is more favorable than Gain Therapeutics.
In the previous week, Acurx Pharmaceuticals had 2 more articles in the media than Gain Therapeutics. MarketBeat recorded 3 mentions for Acurx Pharmaceuticals and 1 mentions for Gain Therapeutics. Acurx Pharmaceuticals' average media sentiment score of 0.19 beat Gain Therapeutics' score of 0.00 indicating that Acurx Pharmaceuticals is being referred to more favorably in the news media.
Summary
Gain Therapeutics beats Acurx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Acurx Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACXP and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Acurx Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:ACXP) was last updated on 2/5/2025 by MarketBeat.com Staff
